Cytokinetics, Inc. (CYTK) EVP Sells $10,965.00 in Stock

Cytokinetics, Inc. (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $7.31, for a total value of $10,965.00. Following the sale, the executive vice president now directly owns 85,567 shares in the company, valued at approximately $625,494.77. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Fady Ibraham Malik also recently made the following trade(s):

  • On Thursday, December 6th, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The shares were sold at an average price of $7.38, for a total value of $11,070.00.
  • On Thursday, November 1st, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The shares were sold at an average price of $6.68, for a total value of $10,020.00.

CYTK opened at $7.28 on Monday. Cytokinetics, Inc. has a one year low of $5.90 and a one year high of $10.26. The company has a debt-to-equity ratio of 0.73, a quick ratio of 10.58 and a current ratio of 10.57. The firm has a market capitalization of $402.13 million, a PE ratio of -2.81 and a beta of 2.05.



Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.11. The firm had revenue of $10.64 million during the quarter, compared to the consensus estimate of $2.23 million. On average, research analysts forecast that Cytokinetics, Inc. will post -1.95 EPS for the current year.

CYTK has been the topic of several recent analyst reports. ValuEngine raised Cytokinetics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 3rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 target price on shares of Cytokinetics in a research note on Wednesday, October 3rd. HC Wainwright cut their target price on Cytokinetics from $24.00 to $21.00 and set a “buy” rating on the stock in a research note on Friday, October 5th. They noted that the move was a valuation call. Finally, BidaskClub downgraded Cytokinetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 9th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $12.96.

Institutional investors and hedge funds have recently bought and sold shares of the company. Jefferies Group LLC bought a new stake in shares of Cytokinetics in the 3rd quarter worth $110,000. Virtu Financial LLC acquired a new position in shares of Cytokinetics in the 3rd quarter worth $111,000. State of Alaska Department of Revenue grew its holdings in shares of Cytokinetics by 9.4% in the 4th quarter. State of Alaska Department of Revenue now owns 18,233 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 1,564 shares during the last quarter. MetLife Investment Advisors LLC grew its holdings in shares of Cytokinetics by 57.9% in the 3rd quarter. MetLife Investment Advisors LLC now owns 29,553 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 10,837 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Cytokinetics by 15.2% in the 2nd quarter. Swiss National Bank now owns 85,400 shares of the biopharmaceutical company’s stock worth $709,000 after acquiring an additional 11,300 shares during the last quarter. 70.44% of the stock is currently owned by institutional investors.

WARNING: This piece was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://dakotafinancialnews.com/2019/01/14/cytokinetics-inc-cytk-evp-sells-10965-00-in-stock.html.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Further Reading: What is a Roth IRA?

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply